Stem Cell Clinic

Stem cells, juicing, Piloxing, triathlon, workout apps–health and wellness on overdrive

By Uncategorized

Back to basicsCaveman workout is the choice for functional training.

Swim, bike and runtriathlon became even more popular in 2013.

It was the year stem cell therapy became a household name.

Although the science has been around for half a century in Europe, it was not until the Asian Institute of Longevity Medicine (AILM) opened its doors to Filipinos in 2009 that stem cell therapy took off in the country.

Today, AILMs German-based partner, Tissue and Cell Banking (Ticeba), headed by its founder and managing director Dr. Christoph Ganss, is one of the countrys most sought-after stem cell therapy consultants.

If you think that, because of its exceedingly high price tag, stem cell therapy would catch on only among the well-heeled, think again. Entrepreneurial Pinoys saw the potential moneymaker in the name, and soon peddlers began brandishing everything from stem cell water to stem cell fertility kits.

Another top hit of 2013 is juicing/detox. Now a multibillion-dollar industry in the United States, juicingwhile it has been practiced by many vegans and vegetarians in the Philippines since the early 2000sbecame big this year when the Australian documentary filmmaker and juicing advocate Joe Cross visited the country.

Today, there are three major competing organic juice brands on the market.

Organic produce

Vegan food the five-star way

See the article here:
Stem cells, juicing, Piloxing, triathlon, workout apps–health and wellness on overdrive

Stem Cell Research – Stem Cell Treatments – Treatments Using …

By Stem Cell Treatment

COMPARE CORD BLOOD BANKS

Choosing the right stem cell bank for your family is rarely a quick decision. But when you review the facts, you may find it much easier than you expected. Keep Reading >

1. The collection of cord blood can only take place at the time of delivery, and advanced arrangements must be made.

Cord blood is collected from the umbilical cord immediately after a babys birth, but generally before the placenta has been delivered. The moment of delivery is the only opportunity to harvest a newborns stem cells.

2. There is no risk and no pain for the mother or the baby.

The cord blood is taken from the cord once it has been clamped and cut. Collection is safe for both vaginal and cesarean deliveries. 3. The body often accepts cord blood stem cells better than those from bone marrow.

Cord blood stem cells have a high rate of engraftment, are more tolerant of HLA mismatches, result in a reduced rate of graft-versus-host disease, and are rarely contaminated with latent viruses.

4. Banked cord blood is readily accessible, and there when you need it.

Matched stem cells, which are necessary for transplant, are difficult to obtain due to strict matching requirements. If your childs cord blood is banked, no time is wasted in the search and matching process required when a transplant is needed. 5. Cells taken from your newborn are collected just once, and last for his or her lifetime.

For example, in the event your child contracts a disease, which must be treated with chemotherapy or radiation, there is a probability of a negative impact on the immune system. While an autologous (self) transplant may not be appropriate for every disease, there could be a benefit in using the preserved stem cells to bolster and repopulate your childs blood and immune system as a result of complications from other treatments.

Originally posted here:
Stem Cell Research - Stem Cell Treatments - Treatments Using ...

Stem cell treatment set for launch in Japan

By Stem Cell Treatment

A treatment owned by Mesoblast Pharmaceutical is set to become the first stem cell treatment to be available in Japan, following an application by its local partner, JCR Pharmaceutical, to launch the product in that market.

According to Japanese reports, JCR Pharmaceutical will lodge its application to market a treatment for so-called graft versus host disease (GVHD), which is a side effect of bone marrow or umbilical cord blood transplant surgery, by the end of December.

Recently, the Japanese government changed the law to fast-track approvals for stem cell treatments, an area where some other countries in the region, such as South Korea, have made similar changes, spawning a great deal of end-market activity.

Earlier this year, Mesoblast agreed to pay up to $US100 million to buy a suite of stem cell patents and products from US drug company Osiris Therapeutic, which brought with it entry into the Japanese drugs market.

Advertisement

According to the reports, the Japan Society of Hematopoietic Cell Transplantation estimates about 1200 people annually develop acute GVHD in that country.

In recent research, broker Bell Potter estimated this could be a $US59 million-a-year market and, with the number of transplants growing, this should see a rise in demand for the treatment. If approved, this would be the first allogeneic stem cell product to be launched in Japan, according to the broker.

JCR could obtain approval within a year from filing to launch the treatment, which would rank it as one of the first of Mesoblast's products to be launched.

Instead of phased clinical trials, the law changes enable regenerative medicines to demonstrate efficacy in pilot studies of as few as 10 patients if the change is dramatic enough, or a few hundred with more marginal treatments.

Link:
Stem cell treatment set for launch in Japan

Stem cell treatment set for Japan

By Stem Cell Treatment

A treatment owned by Mesoblast Pharmaceutical is set to become the first stem cell treatment to be available in Japan, following an application by its local partner, JCR Pharmaceutical, to launch the product in that market.

According to Japanese reports, JCR Pharmaceutical will lodge its application to market a treatment for so-called graft versus host disease (GVHD), which is a side effect of bone marrow or umbilical cord blood transplant surgery, by the end of December.

Recently, the Japanese government changed the law to fast-track approvals for stem cell treatments, an area where some other countries in the region, such as South Korea, have made similar changes, spawning a great deal of end-market activity.

Earlier this year, Mesoblast agreed to pay up to $US100 million to buy a suite of stem cell patents and products from US drug company Osiris Therapeutic, which brought with it entry into the Japanese drugs market.

Advertisement

According to the reports, the Japan Society of Hematopoietic Cell Transplantation estimates about 1200 people annually develop acute GVHD in that country.

In recent research, broker Bell Potter estimated this could be a $US59 million-a-year market and, with the number of transplants growing, this should see a rise in demand for the treatment. If approved, this would be the first allogeneic stem cell product to be launched in Japan, according to the broker.

JCR could obtain approval within a year from filing to launch the treatment, which would rank it as one of the first of Mesoblast's products to be launched.

Instead of phased clinical trials, the law changes enable regenerative medicines to demonstrate efficacy in pilot studies of as few as 10 patients if the change is dramatic enough, or a few hundred with more marginal treatments.

More:
Stem cell treatment set for Japan

Stem Cell Medicine Center

By Stem Cell Medicine

Cord Blood Registry Helps Families Use Stem Cells By: Cord Blood Continue reading

Cord Blood Stem Cells Jessica Denay Talks About Cord Blood Banking By: Cord Blood Continue reading

Meet Angel Keeping Your Baby's Stem Cells Safe at Cord Blood Registry By: Cord Blood Continue reading

Occult Science: Skin Cell Gun Stem cells from a biopsy of the patient's healthy skin are isolated, placed into a sterile syringe with a fitted nozzle, and sprayed directly through the noz By: Occult Sin Continue reading

Harnessing the Potential of Stem Cells For New Medicines: Doug Melton at TEDxBeaconStreet Doug Melton talks about the potential of stem cell biology for regenerative medicine, with a focus on finding new treatments for diseases such as diabetes. D By: TEDxTalks Continue reading

stem cell therapy in chandigarh Performing a hair transplant is as much about craftsmanship and design as it is about microsurgery. Each case is different and a successful result depends on By: rinkle hairtransplant Continue reading

Curing hearts with stem cells Trials to regenerate hearts using stem cells will soon hit the clinic, says David Tancredi. By: youris.com European Research Media Center Continue reading

Regenerating brains with stem cells Reprogramming stem cells is one of the most promising advance towards curing neurodegenerations, says Bernd Evert. By: youris.com European Research Media Center Continue reading

Stem Cell Therapy for Feline Kidney Disease Stem cells show promising results for a number of diseases conditions in humans. Can they do the same for our animal friends? By: Nicky Sims Continue reading

UHS Biology Gaming Show stem cells This is a biology gaming show on the topic of stem cell. Continue reading

Read the original:
Stem Cell Medicine Center

West Coast Stem Cell Clinic, TeleHealth, Now Offering PRP …

By Stem Cell Clinic

Description: An unhandled exception occurred during the execution of the current web request. Please review the stack trace for more information about the error and where it originated in the code.

Exception Details: System.NullReferenceException: Object reference not set to an instance of an object.

Source Error:

1. Add a "Debug=true" directive at the top of the file that generated the error. Example:

<%@ Page Language="C#" Debug="true" %>

or:

2) Add the following section to the configuration file of your application:

Note that this second technique will cause all files within a given application to be compiled in debug mode. The first technique will cause only that particular file to be compiled in debug mode.

Important: Running applications in debug mode does incur a memory/performance overhead. You should make sure that an application has debugging disabled before deploying into production scenario.

Excerpt from:
West Coast Stem Cell Clinic, TeleHealth, Now Offering PRP ...

Plantar Fasciitis Now Being Treated With Stem Cells

By Stem Cell Treatment

Plantar fasciitis, a chronic pain condition involving the sole of the foot, is now being treated using regenerative medicine like stem cell therapy, and offering the first form of real relief for many sufferers.

Plantar fasciitis affects millions of Americans, and is a condition in which the plantar fascia the thick tissue covering the sole of the foot is inflamed, causing severe pain on the bottom of the foot, and impeding activities such as running and walking.

The plantar fascia tissue is what connects the heel bone to the toes, thus creating the arch of the foot.

Traditional treatments for the debilitating injury have offered some relief in recent years through the use of physical therapy, NSAIDS, and steroid injections. However, these types of pain relief develop slowly over time, and are not an effective way to truly treat the problem. Stem cell therapy is going beyond these typical treatments, treating the root cause of the issue, and are often able to alleviate pain more quickly and with longer-lasting results.

Clinics in Arizona and California are just two examples of offices now offering stem cell injections of adult bone marrow and both fat- and amniotic-derived materials. Board certified pain management doctors at the Arizona Pain Stem Cell Institute, in Phoenix, and TeleHealth, in southern California, are giving patients suffering from the condition a low risk, outpatient alternative to corrective surgery.

Many other U.S. states now have pain treatment centers offering the plantar fasciitis stem cell therapy, as well.

Main image courtesy Nevit Dilmen via Wikimedia Commons.

Read more from the original source:
Plantar Fasciitis Now Being Treated With Stem Cells

Cell Therapy – StemCell Doctors

By Stem Cell Doctors

Dr. Aidan R. Raney performs a checkup on heart attack patient Mark Athens, 52, on Tuesday, Dec. 17, at Scripps Green Hospital in La Jolla. Athens received a stem cell treatment to help his heart recover as part of a clinical trial to determine the treatments safety and effectiveness.

A new stem cell treatment may help heart attack patients do something once thought medically impossible regenerate dead heart muscle.

Scripps Health in La Jolla is one of three centers testing the therapy from Capricor, a Los Angeles biotech company. The cardiac stem cells are meant to boost the hearts natural ability to perform minor repairs. If it works, scars should shrink and functional heart muscle should grow.

Capricor gets the cells from donor hearts, grows them into the amount needed for treatment, then sends them to doctors taking part in what is called the Allstar trial. Doctors inject the cells into the coronary artery, where they are expected to migrate to the heart and encourage muscle regrowth.

The trial has successfully completed Phase 1, which mainly evaluates safety. On Dec. 17, Capricor said it had received permission to begin Phase 2, which will examine efficacy in about 300 patients who will get the treatment or a placebo. More information can be found at clinicaltrials.gov under the identifier NCT01458405.

The Allstar trial is funded with a $19.7 million disease team grant from the California Institute for Regenerative Medicine, or CIRM, the states stem cell agency.

This is a highly significant announcement for us at CIRM as its the first time weve funded a therapy into a Phase 2 clinical trial, Chairman Jonathan Thomas said in a Dec. 23 statement.

About 600,000 Americans die of heart disease annually, making it the leading cause of death, according to the Centers for Disease Control and Prevention in Atlanta. Even those surviving may be left permanently impaired, if the heart is severely damaged. These are the patients Capricor seeks to help.

Mark Athens received Capricors treatment on Sept. 25, about a month after having a moderate heart attack. The Encinitas resident was the last treated under Phase 1, said Scripps cardiologist Richard Schatz, who performed the procedure. It will take about six months to know whether the treatment worked, Schatz said.

Unlike many trials, Phase 1 was not placebo-controlled, so Athens knows he got the therapy. He appeared cheerful, smiling and bantering with his examining doctor during a Dec. 17 checkup at Scripps Green Hospital.

See the original post here:
Cell Therapy – StemCell Doctors

Stem cells used in study to regenerate heart tissue

By Stem Cell Doctors

Medical investigators are embarking on a study that involves infusing 10 million stem cells directly into a coronary artery of heart attack patients in an effort to regenerate tissue that otherwise would be forever damaged.

Regeneration has been an ongoing theme in science fiction and a goal of real-life scientists.

Dr. Luis Gruberg, of the Stony Brook Heart Institute, and Dr. Allen Jeremias, director of the intensive care unit, led a team late last month in a novel case, which they describe as a clinical trial designed to harvest, and then inject, a patient's own stem cells into the blocked artery responsible for the attack.

"This is a post-heart attack procedure and it is for patients who have had a large heart attack," said Gruberg, director of interventional cardiology research.

In patients whose attacks are severe, vast portions of the heart are irreparably damaged, resulting in cardiac tissue that no longer performs efficiently.

Every year about 715,000 Americans have a heart attack. Of those, 525,000 are a first heart attack and 190,000 are repeat episodes. Every 44 seconds someone in the United States dies of a heart attack, according to federal data.

If stem cells can aid in the remodeling of the heart, regenerating healthy tissue, then medicine can offer patients a new lease on life, the doctors said.

Arriving at a point when such a treatment can be offered, Gruberg added, requires research. The gold standard of clinical study in Western medicine is the placebo-controlled randomized clinical trial, which means some of the Stony Brook heart patients will receive a stem cell transplant, others, a placebo.

Doctors began their study, part of a larger national investigation, abruptly late last month because they had been awaiting the perfect patient.

That person, a 66-year-old man who had been visiting Long Island from the Midwest, arrived at Stony Brook University Hospital as a transfer from Southampton Hospital.

Continued here:
Stem cells used in study to regenerate heart tissue

stem cell therapy treatment for head injury by dr alok sharma, mumbai, india – Video

By Uncategorized


stem cell therapy treatment for head injury by dr alok sharma, mumbai, india
improvement seen after stem cell therapy treatment for head injury by dr alok sharma, mumbai, india. Stem Cell Therapy done date 16 Nov 2010 After Stem Cell ...

By: Neurogen Brain and Spine Institute

Go here to see the original:
stem cell therapy treatment for head injury by dr alok sharma, mumbai, india - Video

→←